Specific recognition of influenza A/H1N1/2009 antibodies in human serum: A simple virus-free ELISA method

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Alvarez, Mario M ^a   López Pacheco, Felipe ^a   Aguilar Yañez, José M ^a   Portillo Lara, Roberto ^a   Mendoza Ochoa, Gonzalo I ^a   García Echauri, Sergio ^a   Freiden, Pamela ^b   Schultz Cherry, Stacey ^b   Zertuche Guerra, Manuel I ^a   Bulnes Abundis, David ^a   Salgado Gallegos, Johari ^a   Elizondo Montemayor Leticia, L ^a   Hernández Torre, Martín ^a  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; HISTIDINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; INFLUENZA VIRUS A H1N1; PROTEIN EXPRESSION; VIRUS INFECTION; VIRUS PARTICLE; BLOOD; EVALUATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA; METHODOLOGY; SERODIAGNOSIS; SEROLOGY; STANDARD;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; SEROLOGIC TESTS;

EID: 77955367419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010176     Document Type: Article

References (46)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. JAMA 289 (2): 179-1186.
2. Keech M, Beardsworth P (2009) The impact of influenza on working days lost: A review of the literature. PharmacoEconomics 26 (11): 911-924.
3. Sadique MdZ, Adams EJ, Edmunds WJ (2008) Estimating the costs of school closure for mitigating an influenza pandemic. BMC Public Health 8(135).
4. Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 25 (27): 5086-5096.
5. Carrat F, Flahault A (2007) Influenza vaccine: The challenge of antigenic drift. Vaccine 25 (39-40): 6852-6862.
6. Szucs T (1999) The socio-economic burden of influenza. Journal of Antimicrobial Chemotherapy 44 (TOPIC B): 11-15.
7. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. (2009) Pandemic potential of a strain of influenza A (H1N1): Early findings. Science 324 (5934): 1557-1561.
8. Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, et al. (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459 (7250): 1122-1125.
9. Yang Y, Sugimoto JD, Elizabeth-Halloran M, Basta NE, Chao DL, et al. (2009) The transmissibility and control of pandemic influenza a (H1N1) virus. Science 326 (5953): 729-733.
10. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW (2010) Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. Feb 17. [Epub ahead of print].
11. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, et al. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a crosssectional serological study. Lancet 2010 Jan 20. [Epub ahead of print].
12. Ross T, Shanta Z, Burke D, Crevar C, Carter D, et al. (2010) Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza. PLoS Curr Influenza. pp RRN1148.
13. Salk JE (1944) A Simplified Procedure for Titrating Hemagglutinating Capacity of Influenza-Virus and the Corresponding Antibody. The Journal of Immunology 49: 87-98.
14. Schultsz C, Van Dung N, Hai LT, Quang Ha D, Peiris JSM, et al. (2009) Prevalence of Antibodies against Avian Influenza A (H5N1) Virus among Cullers and Poultry Workers in Ho Chi Minh City, 2005. PLoS ONE 4(11): e7948. doi:10.1371/journal.pone.0007948.
15. Kitphati R, Pooruk P, Lerdsamran H, Poosuwan S, Louisirirotchanakul S, et al. (2009) Kinetics and Longevity of Antibody Response to Influenza a H5N1 Virus Infection in Humans. Clinical and vaccine immunology 16(7): 978-981.
16. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ (2009) Subunit Influenza vaccines produced from cell culture or in embryonated chicken eggs: Comparison of safety, reactogenicity, and immunogenicity. Journal of Infectious Diseases 200(6): 849-857.
17. Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barret PN, et al. (2010) Comparison of single, homologous prime-boost and heterologous primeboost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 28 (3): 650-656.
18. Hassantoufighi A, Zhang H, Sandbulte M, Gao J, Manischewitz J, et al. (2009) A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. 2009. Vaccine 28(3): 790-797.
19. Noah DL, Hill H, Hines D, White EL, Wolff MC (2009) Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clinical and Vaccine Immunology 16(4): 558-566.
20. Stephenson I, Wood JM, Nicholson KG, Zambon MC (2003) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. Journal of Medical Virology 70 (3): 391-398.
21. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. New England Journal of Medicine 361(20): 1945-1952.
22. Sirskyj D, Weltzin R, Golshani A, Anderson D, Bozic J, et al. (2010) Detection of influenza A and B neutralizing antibodies in vaccinated ferrets and macaques using specific biotin-streptavidin conjugated antibodies. Journal of Virological Methods 163(2): 459-464.
23. Prabakaran M, Ho H-T, Prabhu N, Velumani S, Szyporta M, et al. (2009) Development of Epitope-Blocking ELISA for Universal Detection of Antibodies to Human H5N1 Influenza Viruses. PLoS ONE 4(2): e4566. doi:10.1371/ journal.pone.0004566.
24. Stelzer-Braid S, Wong B, Robertson P, Lynch GW, Laurie K, et al. (2008) A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies. Journal of Clinical Virology 43 (2): 241-243.
25. He Q, Velumani S, Du Q, Chee WL, Fook KN, et al. (2007) Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clinical and Vaccine Immunology 14 (5): 617-623.
26. De Boer GF, Back W, Osterhaus ADMD (1990) An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Archives of Virology 115 (1-2): 47-61.
27. World Health Organization website (2009) CDC protocol of realtime RT-PCR for influenza A (H1N1). http://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/index.html.
28. Li OT, Poon LL (2009) One step closer to universal influenza epitopes. Expert Rev Anti Infect Ther 7(6): 687-90.
29. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. (2009) Cross- Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Viruses. PLoS Pathog 5(3): e1000350. doi:10.1371/journal.ppat.1000350.
30. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325 (5937): 197-201.
31. Schwarzer J, Rapp E, Hennig R, Genzel Y, Jordan I, et al. (2009) Glycan analysis in cell culture-based influenza vaccine production: Influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27(32): 4325-4336.
32. Wang Ch-Ch, Chen J-R, Tseng Y-Ch, Hsu Ch-H, Hung Y-F, et al. (2009) Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci 106 (43): 18137-18142.
33. Shih AC, Hsiao TC, Ho MS, Li WH (2007) Simultaneous aminoacid substitutions at antigenic sites drive Influenza A hemagglutinin evolution. Proc Natl Acad Sci 104: 6283-6288.
34. Wiley DC, Skehel JJ (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. (1987) Annual Review of Biochemistry 56: 365-394.
35. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31: 417-427.
36. Gerhard W, Yewdell J, Frankel ME, Webster R (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290: 713-717.
37. Hidayatullah TA (2009) Cloning and expression of antigenic sites of hemagglutinin of Influenza A virus. International Journal of Integrative Biology 6(3): 137-142.
38. Shen J, Ma J, Wang Q (2009) Evolutionary Trends of A(H1N1) Influenza Virus Hemagglutinin Since 1918. PLoS ONE 4(11): e7789. doi:10.1371/ journal.pone.0007789.
39. Schwahn AB, Downard KM (2009) Antigenicity of a type A influenza virus through comparison of hemagglutination inhibition and mass spectrometry immunoassays. Journal of Immunoassay and Immunochemistry 30 (3): 245-261.
40. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378.
41. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The Influenza Hemagglutinin. Annual Review of Biochemistry 69: 531-569.
42. Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs. Plos One 3(5): e2257.
43. Chiu FF, Venkatesan N, Wu CH-R, Chou A-H, Chen H-W, et al. (2009) Immunological studies of HA1 domain of hemagglutinin of influenza H5N1 virus. Biochemical and Biophysical Research Communications 383: 27-31.
44. Alvarez MM, Aguilar-Yáñez JM, García-Echauri SA, Salgado-Gallegos J E. coli: BL21 (DE3) pLysS C41. ATCC HPatent Deposit Designation: PTA-10320. Escherichia coli strain transformed for the production of a protein that acts as a vaccine against Influenza A H1N1/2009 virus. September 2009.
45. Aguilar-Yañez JM, García-Echauri S, Mendoza G, Portillo-Lara R, Salgado J, et al. (2009) "Proteínas recombinantes expresables en Escherichia coli como ingredientes activos de vacunas contra influenza a h1n1 brote 2009 y su proceso de producción". File MX/a/2009/009565; Mexican patent requested on September 8, 2009.
46. Paal M, Heel T, Schneider R, Auer B (2009) A novel Ecotin-Ubiquitin-Tag (ECUT) for efficient, soluble peptide production in the periplasm of Escherichia coli. Microbial cell factories 8: 7.